Steven Conant
Psychiatry · Avon, INNPI 1871569772
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,338 and has fallen 96.7% since, to $44 in 2025.
Across 132 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$489
- Vanda Pharmaceuticals Inc.$309
- Otsuka America Pharmaceutical, Inc.$294
- Neurocrine Biosciences, Inc.$282
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$279
- Teva Pharmaceuticals USA, Inc.$279
- plus $668 from 9 others
What the payments were for
- Food & beverage$2,45494%
- Education$1476%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $489 |
| Vanda Pharmaceuticals Inc. | 13 | $309 |
| Otsuka America Pharmaceutical, Inc. | 9 | $294 |
| Neurocrine Biosciences, Inc. | 20 | $282 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $279 |
| Teva Pharmaceuticals USA, Inc. | 11 | $279 |
| Alkermes, Inc. | 12 | $222 |
| Johnson & Johnson | 5 | $97 |
| Lundbeck LLC | 5 | $96 |
| Indivior Inc. | 5 | $91 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Tris Pharma Inc | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Corium, LLC | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,601 in reported general payments places this provider in the 80th percentile of 514 psychiatry providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 37 | $83,570 |
| Invega SustennaPaliperidone Palmitate | 29 | $77,412 |
| VraylarCariprazine Hcl | 42 | $67,309 |
| RexultiBrexpiprazole | 24 | $35,408 |
| CaplytaLumateperone Tosylate | 17 | $29,317 |
| Lurasidone Hcl | 71 | $28,806 |
| Risperdal ConstaRisperidone Microspheres | 15 | $25,697 |
| TrintellixVortioxetine Hydrobromide | 47 | $24,716 |
| Aripiprazole | 104 | $7,303 |
| Chlorpromazine Hcl | 17 | $6,714 |
| Paliperidone ErPaliperidone | 20 | $4,870 |
| Ziprasidone Hcl | 79 | $3,811 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 35 | $3,713 |
| Oxcarbazepine | 45 | $3,256 |
| Divalproex Sodium ErDivalproex Sodium | 34 | $3,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $97 | $103,10944 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $309 | $83,57037 claims |
| AbbVieVraylar | $489 | $67,30942 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $294 | $35,40824 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $279 | $29,31717 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $31 | $24,71647 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Avon
- Steven PaulCarmel$2.9M
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$739K
- Christopher BojrabCarmel$713K
- Joseph FanelliMunster$443K
- Eric JaggersJeffersonville$260K
- Larry LambertsonFort Wayne$208K
- Louis CadyNewburgh$135K
- Charles BeasleyIndianapolis$129K
- Muhammad MunirAnderson$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.